Future novel therapeutics capable of modifying the balance of Th17/Treg function or direct targeting the IL-17A related inflammatory response might be beneficial for children with persistent OME or recurrent AOM requiring repeated ventilation tube insertion30,31. Here, IL17A is linked to otitis media with effusion.